Use the search to find what you are looking for



Two exciting new CUP trials awaiting ethical approval before a Summer start

April 16, 2018

The immunotherapy trial, to which we have contributed £100,000 on behalf of our donors, is now awaiting only ethical approval. Merck are providing/funding the drugs. The trial’s initiator and lead, Dr Harpreet Wasan of Hammersmith Hospital and Imperial College London, writes: ‘We hope to recruit 77 patients in total to test the benefit of immunotherapy in CUP and hope also to find tests (bio markers ) in the patients who get benefit from the immunotherapy…The trial is awaiting ethical approval and we hope to be recruiting patients by the end of this Summer’. [Apr 18]
It has been agreed that the trial will run from 3 London Centres: Hammersmith (co-ordinating Centre), Guy’s /St Thomas’s and the Royal Marsden.

The Roche trial that has been worked-up over the last year is likely to start recruiting in the UK sometime this Summer. Some 100 centres in 25 countries have been agreed with the aim of recruiting 790 patients overall. Regulatory/ethics submission is now underway in 17 European countries. It is likely that there will be 8 UK centres, spread across the UK, but we are not able to name them until approvals are in place. The trial, over some 30 months, will compare the efficacy of immunotherapy versus chemotherapy. Screening will include molecular profiling using the Foundation Medicine assay. All patients will receive initially 3 cycles of chemotherapy. More comprehensive details are shown at

← Back to blog